Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | The impact of MRD & genetics on outcomes to time-limited combinations in patients with CLL

Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, comments on the importance of considering both measurable residual disease (MRD) status and IgHV mutational status to predict outcomes in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib-venetoclax combinations. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Janssen, Roche, AbbVie, BeiGene, AstraZeneca: Research Funding; Janssen, Roche, AbbVie, BeiGene, AstraZeneca, MSD: Speakers Bureau; Beigene: Other: Travel Support; Janssen, AbbVie, Lilly, AstraZeneca, BeiGene, MSD: Consultancy.